Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.075
Bid: 2.95
Ask: 3.20
Change: 0.245 (8.52%)
Spread: 0.25 (8.475%)
Open: 2.875
High: 3.12
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Fri, 20th Nov 2020 14:51

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Land Securities Group PLC - London-based commercial property developer - Chief Executive Officer Mark Allan buys 45,695 shares at GBP6.82, worth GBP311,772, on Thursday. Landsec last week reported a wider interim loss and a fall in net asset value but reinstated its dividend.

----------

SSE PLC - electricity utility based in Perth, Scotland - Colin Nicol, outgoing managing director of electricity distribution business, SSEN Distribution, sells 18,212 shares at GBP14.11, worth GBP256,990, on Wednesday.

----------

RSA Insurance Group PLC - London-based general insurance - Chief Legal Officer Charlotte Heiss sells 29,968 shares at GBP6.75, worth GBP202,344, on Thursday. RSA on Wednesday said it has reached an agreement to be sold and split up in a deal with a two-headed consortium which values the former Royal & Sun Alliance Insurance Group at GBP7.2 billion.

----------

Spirent Communications PLC - Crawley, England-based provider of testing, analytics and security for telecommunications networks - Dean Ritchie, associate of Chief Financial Officer Paula Bell, buys 50,000 shares at GBP2.57, worth GBP128,740, on Thursday. Bell now interested in 363,884 shares.

----------

Jardine Matheson Holdings Ltd - Hong Kong-headquartered holding company with interests in retail, property, hotels and motor dealerships - Ruby Weatherall, associate of Director Percy Weatherall, sells 3,100 shares at USD51.35, worth USD159,193, in Singapore on Thursday.

----------

H&T Group PLC - Surrey, England-based pawnbroker - CFO Richard Withers buys 10,000 shares for 227.4 pence, worth GBP22,740, on Wednesday.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Non-Executive Chair Peter Jensen buys 100,000 shares at 14p, worth GBP14,000, on Thursday.

----------

easyJet PLC - Luton Airport-based budget airline - Non-Executive Director Nicholas Leeder buys 1,346 shares mostly at GBP7.53, worth GBP10,140, on Thursday.

----------

Henderson High Income Trust PLC - investment trust aiming for high-income stream and prospects of capital growth - Director Jeremy Rigg buys 10,000 shares at GBP1.46, worth GBP14,605, on Friday.

----------

Dunedin Enterprise Investment Trust PLC - invests in UK mid-market companies - Directors sell shares as part of company's tender offer at GBP3.85 on November 12. Brian and Fionnlagh Finlayson sell 27,572 shares. Duncan, Rosemary and Victoria Budge sell 12,449 shares. Angela and David Lane sell 4,307. Company bought back 2.5 million shares in total, spending about GBP9.8 million.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Aug 2021 14:33

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

Read more
3 Aug 2021 13:43

Allergy Therapeutics upbeat on ex-vivo study of peanut allergy vaccine

(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.

Read more
14 Jul 2021 12:29

Allergy Therapeutics expects revenue rise in year despite challenges

Allergy Therapeutics expects revenue rise in year despite challenges

Read more
24 Jun 2021 19:56

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

Read more
24 Jun 2021 08:07

Allergy Therapeutics FY profits seen 'well ahead' of expectations

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.

Read more
6 May 2021 19:25

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

Read more
6 May 2021 15:34

Allergy Therapeutics completes treatment in G309 field study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.

Read more
3 Mar 2021 19:14

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

Read more
3 Mar 2021 13:23

Allergy Therapeutics reports record pre-R&D operating profit

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.

Read more
13 Jan 2021 13:29

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

Read more
5 Jan 2021 18:01

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

Read more
5 Jan 2021 16:44

Allergy Therapeutics begins peanut allergy vaccine study

(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.

Read more
8 Dec 2020 21:07

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

Read more
1 Dec 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.